Sentence examples for modest overall response from inspiring English sources

In a small study of chemonaive patients, single-agent gemcitabine produced a modest overall response rate of 18% (D'Agostino et al, 2003).

The modest overall response rate of 18.9% and high disease-control rate of 75.7% concur with the recently reported response patterns of everolimus (Yao et al, 2011b) and sunitinib for pancreatic NETs (Raymond et al, 2011).

Despite the modest overall response rate of 9% (disease control rate = 47%), patients receiving erlotinib demonstrated significantly improved OS [7 months vs. 5 months, hazard ratio (HR) = 0.70, P < 0.001], PFS (2.2 months vs. 1.8 months, P < 0.001), and quality of life compared with best supportive care [11].

Moreover, we achieved a modest 28% overall response rate (or 37% of those who were contactable) which limits the generalisability of our study findings.

Typically, response rates to second-line chemotherapy in platinum-resistant recurrent ovarian cancer is modest although overall response rates up to 40% have been reported in the literature (Salom et al, 2002).

Recently, Edelman et al (2001a) reported the results of phase II study for sequential combination chemotherapy consisting of carboplatin and GEM followed by paclitaxel showed modest activity (overall response: 31%, median survival time: 9.5 months).

However, even with antidepressants, the overall response rate is modest.

Although the best overall response rates were modest, 10.9 % in the ipilimumab-alone group and 5.7 % in the ipilimumab plus gp100 vaccine group, some patients in both groups maintained an objective response for at least 2 years [ 4].

Despite the low-response rate and the modest overall survival benefit and fast development of resistance, gemcitabine was adopted as the standard therapy of advanced pancreatic cancer.

The relatively modest number of deaths estimated by the WHO prompted some to question whether the overall response to the 2009 outbreak was excessive.

Paclitaxel yielded overall response rates (ORR) that ranged from 16 to 27%, overall OS times of 5 11 months, and modest toxicity in several phase II trials.